Web Research

The Bottom Line from the Web

The filings describe a steady-state medical-device company. The internet describes a company under siege. Between late October 2025 and December 2025, two activist funds — Jana Partners and Browning West (with over $500M invested) — launched parallel campaigns demanding a break-up of Cooper Companies, a merger of CooperVision with Bausch + Lomb, a board overhaul, and a strategic review of CooperSurgical. On December 4, 2025, the company capitulated: it announced a formal strategic review and a new board chair, sending the stock up roughly 12% after hours. As of April 2026, the activist story is the dominant driver of the stock — not contact-lens organic growth, not fertility-market dynamics, not FX. Anyone valuing COO off historical earnings power without pricing in a potential break-up is working with a stale thesis.

What Matters Most

1. Dual activist campaigns demanding a break-up

In October–November 2025, Jana Partners and Browning West launched overlapping activist campaigns against Cooper. Jana disclosed a "top portfolio position" and is reportedly pushing to combine CooperVision with Bausch + Lomb (BLCO), whose CEO Brent Saunders publicly welcomed a combination. Browning West, with over $500 million invested, nominated four directors (Walt Rosebrough ex-Steris; Joe Papa ex-Bausch+Lomb/Bausch Health; Andy Pawson ex-Alcon; Faraz Athar of Browning West) and is urging the board to evaluate strategic alternatives for CooperSurgical while refocusing on CooperVision as a pure-play. Source: fiercebiotech.com 2025-11-20; cnbc.com 2025-11-15; streetinsider.com 2025-11-19.

2. Company caved: strategic review launched, new board chair named

On December 4, 2025, Cooper announced a "comprehensive strategic review" and appointed a new board chair. Shares rose ~12% after hours. On the Q4 2025 earnings call the next day, analysts directly asked management to elaborate on "the potential for splitting up CooperVision (CVI) and CooperSurgical (CSI)." This is no longer hypothetical — management is now actively evaluating scenarios that could include divestiture, spin-off, or a full corporate split. Source: gurufocus.com 2025-12-04, 2025-12-05.

3. Q4 2025 was a disaster on earnings even as revenue held

For Q4 2025 (reported Dec 4, 2025), Cooper posted revenue of $1.07B (about $6.8M light) but diluted EPS of $0.43, missing the $1.13 consensus by roughly $0.70 — a 62% EPS miss. This is the worst miss in recent memory and was almost certainly a contributor to the activist pressure landing. Q1 2026 (reported March 5, 2026) recovered: non-GAAP EPS of $1.10 vs. $1.03 consensus (up 20% YoY), revenue $1.02B up 6.2% YoY, with $159M free cash flow and $92M used to repurchase 1.1M shares. Source: quiverquant.com 2025-12-04; fool.com 2026-03-05; marketbeat.com 2026-04-22.

4. Stock has materially underperformed — down 22% over one year

As of late April 2026, COO trades near $64.35, down 8.2% over five days, 12.5% over six months, 21.5% YTD, 22.1% over one year, and 37.4% over five years, while the S&P 500 is up ~4.5% over one year. The P/E compressed to a "decade-low 16x" on some measures before the Dec 4 rally, against a 5-year range that included much richer multiples. Underperformance is the structural reason activists showed up. Source: finance.yahoo.com 2026-04-21; ainvest.com 2025-11-21.

5. CFO also took principal accounting officer role on Dec 9, 2025

On December 9, 2025 — five days after the strategic review announcement — CFO Brian G. Andrews assumed the role of principal accounting officer from Agostino Ricupati, who stays on as SVP Tax. Dual-hatting the CFO as PAO mid-strategic-review is unusual; it consolidates financial authority inside Andrews at the exact moment the company is preparing to sell or separate business units. Not inherently negative, but worth watching. Source: sec.gov 8-K filed 2025-12-09.

6. Board authorized a $1 billion buyback increase in September 2025

On September 17, 2025 — weeks before activists surfaced publicly — the board approved a $1 billion increase to the share repurchase authorization. Cooper deployed $92M in Q1 2026 to buy back 1.1M shares. The pre-activist buyback expansion is a reasonable defense against valuation pressure, but it has not stopped the stock slide. Source: globenewswire via stockanalysis.com, 2025-09-17; fool.com Q1 2026 transcript.

7. Analyst consensus is intact but dispersion is wide

Consensus 12-month target: ~$87–$91 (implying roughly 35–42% upside from $64). MarketBeat shows 1 Strong Buy, 8 Buy, 7 Hold, 1 Sell, consensus "Moderate Buy," PT ~$90.79. The spread is notable: Barclays raised its target to $103 (Overweight), while Goldman Sachs maintains a $73 Sell. Needham's last upgrade was June 17, 2025 to $94. Zacks raised FY2026 EPS estimates in March 2026 to $4.58 (from $4.45), FY2027 to $4.89, FY2028 to $5.34. Source: benzinga.com; marketbeat.com 2026-04-22; fntl.in; themarketsdaily.com 2026-03-27.

8. Shareholders backed incumbent management at the annual meeting

At the most recent annual meeting (approximately early April 2026), stockholders elected all nine director nominees, ratified KPMG as auditor for fiscal 2026, and approved executive compensation in the advisory vote. This is a thumbs-up for management in the short term — but it predates resolution of the strategic review and does not preclude a later board composition change if the review drags. Source: stocktitan.net 8-K filing, two weeks prior to April 2026.

9. Historical governance episodes worth naming

Cooper has two pre-existing governance blemishes: (a) a 1994 SEC settlement where the company paid $2.77M over junk-bond-related fraud charges tied to senior executives in 1991; (b) a December 2011 securities fraud class action filed by Rigrodsky & Long alleging materially false statements. Neither is active today, but both appear when activists rake the background, and Browning West's "poor governance" framing draws on this long tail. Source: nytimes.com 1994-12-13; businesswire.com 2011-12-13.

10. CEO Al White owns 0.13% of company ($18M) — modest for an 8-year tenure

White has been CEO since May 2018 (previously CFO). Simply Wall St reports FY2024 total comp at ~$16M (~7.3% salary, 92.7% performance/equity). Stock ownership of ~0.13% ($18M) is directionally aligned but not large relative to tenure, and EPS growth over the trailing three years has been materially negative per prior analyses. White also joined Evolus (EOLS) as an independent director in July 2024 — a side gig that is not unusual but adds attention drain during an activist campaign. Source: simplywall.st management page; finance.yahoo.com Simply Wall St compensation analysis 2024-03-13.

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

Albert G. White III — CEO and President

Appointed May 2018 (previously CFO 2016–2018; CEO of Cooper Medical 2015–2018). FY2024 total comp ~$16.05M with 7.3% base salary — a pay structure heavily tilted to equity and bonus, which is standard for a medium-to-large cap medical device company. Direct stock ownership ~0.13% ($18M at current prices). Added independent directorship at Evolus Inc. in July 2024. Prior Simply Wall St analysis noted CEO compensation was "in line with the median for the industry" but flagged that EPS fell ~50% over the three-year window ending FY2023 — a disconnect between pay and EPS outcomes that shareholder advisory firms typically scrutinize. Shareholder advisory vote on pay passed at the most recent AGM.

Brian G. Andrews — CFO, Treasurer, and now Principal Accounting Officer

CFO/Treasurer since 2018, EVP since 2020. On December 9, 2025 he took on principal accounting officer duties from Agostino Ricupati (who remains SVP Tax). Consolidating PAO inside the CFO during an active strategic review is atypical enough to flag, though not necessarily negative. Andrews has been the public-facing financial voice on all recent earnings calls including the Q4 2025 call that produced the $0.70 EPS miss.

Daniel G. McBride — COO, EVP, President CooperVision

Reported by Comparably as the highest-paid named executive at $3.7M annually. As President of CooperVision he runs the division the activists want to keep and scale. If a break-up occurs, he is the natural internal candidate to lead a CooperVision-standalone entity.

Holly Sheffield — EVP and Chief Strategy Officer

Appointed June 2018 (announced alongside White's CEO elevation). Role covers corporate strategy and business development — i.e., the exact function that would be leading any strategic review or divestiture process today.

No Results

Industry Context

The global medical-device market is estimated at $572–679B in 2025, projected to reach $1.03–1.21T by 2034–2035, implying a ~5–6% CAGR. Cooper operates in two specific sub-segments:

Contact lenses. Structural tailwinds remain: ~40% of wearers still use non-daily lenses creating a multi-year upgrade runway to silicone-hydrogel dailies; growing global wearer base; high barriers to entry. CNBC's Jana Partners summary puts CooperVision EBITDA margin in the mid-30s. The competitive set (Alcon, J&J, Bausch+Lomb, Hoya) is concentrated enough that a Cooper–Bausch+Lomb combination might actually face less antitrust resistance than it initially appears, because it would create a clearer #2 to Alcon/J&J.
Fertility/IVF and women's health. Fertility treatment is a ~$2B global market growing 4–6% annually. Cooper has broad IVF-cycle coverage but faces questions about strategic fit within a contact-lens parent. The activist prescription is either cleaning up the portfolio internally (Jana's view) or separating CooperSurgical entirely (Browning West's view).

Near-term headwinds per management commentary: macro pressure on consumer spending, global FX (1.5% revenue / 4% EPS drag in FY25), inventory normalization in fertility, and new competitive entrants in IUD and contact lens segments.